| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | QSI | Class A Common Stock | Award | +170K | 170K | Jun 10, 2021 | Direct | F1, F2 | |||
| transaction | QSI | Class A Common Stock | Award | $500K | +50K | +29.35% | $10.00 | 220K | Jun 10, 2021 | Direct | F3 |
| Id | Content |
|---|---|
| F1 | Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest as to 25% on January 7, 2022, with the remainder vesting in 12 equal quarterly installments thereafter, subject to Dr. LaPointe's continued service through the applicable vesting date. |
| F2 | In connection with the closing of the transactions contemplated by the Business Combination Agreement, dated as of February 18, 2021, by and among HighCape Capital Acquisition Corp. ("HighCape"), Tenet Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of HighCape ("Merger Sub"), and Quantum-Si Incorporated, a Delaware corporation ("Quantum-Si"), pursuant to which Merger Sub merged with and into Quantum-Si (the "Merger"), with Quantum-Si surviving as a wholly-owned subsidiary of HighCape (which changed its name to "Quantum-Si Incorporated", the "Issuer"), these shares were received in exchange for 213,600 RSUs of Quantum-Si. |
| F3 | Dr. LaPointe purchased 50,000 shares of Class A common stock from the Issuer, at a price of $10.00 per share, in a private placement immediately prior to the closing of the Merger. |